Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-02-13			5-day change	1st Jan Change
58.23 ^CNY	-0.87%		+1.61%	-2.25%

Feb. 11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
Feb. 10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE

Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX

Published on 01/20/2026 at 10:09 am EST

Reuters

Latest news about Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Feb. 11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
Feb. 10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE
Feb. 10	Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial	RE
Feb. 10	Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide	CI
Feb. 08	Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug	MT
Feb. 05	Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators	MT
Jan. 28	China Designates Jiangsu Hengrui Medicine's Lipid Disease Tablet as Breakthrough Therapy	MT
Jan. 27	Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials	MT
Jan. 22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
Jan. 20	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT
Jan. 20	Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs	MT
Jan. 20	Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX	RE
Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
Jan. 07	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Duration

Period

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276: Dynamic Chart

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release

More about the company